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In a Palestinian family, four siblings were shown to express typical and severe congenital erythropoietic porphyria
(CEP). A new mutation of the uroporphyrinogen III synthase (UROS) gene was evidenced by systematic sequencing
of the UROS gene: the substitution of serine by proline at the amino acid residue 47 (S47P) was present at the
homozygous state in the four patients. The mother was heterozygous, the father was not examined. Surprisingly, in
one unaffected sister, UROS activity was markedly deﬁcient and UROS gene analysis showed a homozygous
mutant proﬁle. The deleterious role of the mutant S47P protein on UROS activity was demonstrated by prokaryotic
expression. This observation is the ﬁrst report of a healthy status associated with homozygosity for a mutation of
UROS gene in a severely affected family. We then draw hypotheses to explain the protective phenotype in the
homozygous healthy subject.
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Case Report
The members of the kindred under consideration (Fig 1)
belong to the Palestinian Muslim community. Parents de-
nied direct consanguinity but originate from the same vil-
lage. The different members of the family were examined at
the same time. In patients II-6–II-8, II-10, and II-12, the dis-
ease began in infancy, with pink-colored diapers. Photo-
sensitivity lesions and blisters appeared precociously in
sun-exposed areas, after minor traumas, and led to severe
deformities and destructions of the nasal and auricular car-
tilage, and/or the distal phalanges. Typical features such as
dyspigmentation and hirsutism, poor dentition, reddish-
brown teeth, mild splenomegaly, and hemolytic anemia
were observed. Patient II-7 was the most severely affected:
massive mutilations and deformities due to bone resorption
were observed on his hands. Subject II-11 had none of the
features described above but few hyper-pigmented lesions
of the face.
In the four affected patients analyzed (II-6, II-7, II-8, and
II-12), typical profiles were observed: massive uroporphyr-
inuria (Table I), barely detectable uroporphyrinogen III synt-
hase (UROS) erythrocytic activity (Table II), homozygosity
for a new mutation of the UROS gene (S47P). The mother
(I-1) and one brother (II-9) were healthy heterozygous car-
riers. One brother (II-13) was a healthy non-carrier (Fig 2 and
Table II). The father (I-2) was not examined.
Prokaryotic expression of the mutant S47P UROS
protein demonstrated clearly that the S47P mutation was
a disease-causing mutation (Table III). The 2.8% residual
activity of the mutant S47P UROS protein eliminated the
hypothesis of a rare polymorphism of the UROS gene.
One sister (II-11) had no cutaneous lesion, moderate
uroporphyrinuria (ten times the normal values, but ten times
less than affected siblings in the family) while she presented
the mutation at the homozygous state and showed a pro-
found deficiency of UROS activity. Hematological examina-
tion showed normal blood parameters, no hemolysis, while
affected sibs had profound anemia, hemolysis, and ab-
normal morphology of circulating red cells (anisocytosis,
poikilocytosis, and dyschromatophilia). In patient II-12,
hematological parameters were: hemoglobin 8 g per 100
mL, reticulocyte count 110,000 per mm3, serum iron 4.4
mmol per 100 mL, undetectable haptoglobin. Of note, the
mother I-1 was heterozygous for the sickle cell trait. Hem-
oglobin electrophoresis profile was normal in both sisters II-
11 and II-12.
Commentary
Congenital erythropoietic porphyria (CEP) is usually a severe
form of CEP, transmitted as an autosomal recessive trait and
characterized by a profound deficiency in UROS activity.
CEP patients can be classified as very mild to severely af-
fected based on age at onset, cutaneous involvement,
transfusion dependency. At least 40 different mutations have
Abbreviations: CEP, congenital erythropoietic porphyria; UROS,
uroporphyrinogen III synthase
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been described in the UROS gene, with one predominant
missense mutation (C73R) associated with a severe pheno-
type. For genotype–phenotype comparisons, expression of
the missense mutations in Escherichia coli can indicate the
amount of residual activity encoded by the mutant alleles. In
this prokaryotic expression system, the levels of UROS
activity range from extremely low (o1% of the expressed
normal allele) to moderate levels (2%–8%). Missense muta-
tions with high levels of residual activity (10%–35%) have
increased thermolability. Patients who are homo- or
heteroallelic for mutations that express residual activity
(8%–35%) have milder forms of the disease (Anderson et al,
2001; Desnick and Astrin, 2002; Verneuil et al, 2003).
This report describes a novel mutation of the UROS gene
(S47P) responsible for severe cutaneous lesions and UROS
enzymatic deficiency in a large kindred. The moderate level
of residual UROS activity in the prokaryotic expression sys-
tem is consistent with the absence of transfusion depend-
ency in affected patients. A female sibling among these
kindred (II-11) presented very unusual features. Despite
a profound deficiency in UROS erythrocytic activity, she
showed neither cutaneous nor hematological signs as if she
were protected from the accumulation of porphyrins. This
could suggest that porphyrin biosynthesis is not hyperactive
in the sibling II-11, unlike what is usually found in CEP pa-
tients. Additional analyses in II-11 ruled out the hypothesis
of an associated hematological disorder such as sickle cell
anemia, thalassemia or dyserythropoiesis that could limit
porphyrin synthesis. Urinary and blood analyses showed
that the association of two enzymatic defects of hem syn-
thesis is unlikely.
The protective factor remains to be elucidated in this
observation. The influence of a modifier gene, whether de-
pendent or distinct from the hem metabolic pathway, is an
attractive hypothesis. The influence of modifier loci has
been proposed in more frequent genetic diseases: cystic
fibrosis (Acton and Wilmott, 2001) or sickle cell anemia
(Nagel and Steinberg, 2001). In porphyria cutanea tarda
(PCT), a deficiency of uroporphyrinogen decarboxylase
(UROD, fifth step of hem synthesis), the expression of the
disease was clearly shown to rely on the modifier gene
HFE1 responsible for hemochromatosis (Brady et al, 2000).
d-Aminolevulinate synthase (ALAS) is the rate-limiting step
in hem synthesis. In hepatocytes, the ALAS1 gene is down-
regulated by hem. In erythropoietic cells, ALAS2 gene reg-
ulation is closely related to both iron and hem homeostasis
(Anderson et al, 2001). The deregulation of ALAS2 gene is
an attractive hypothesis to explain the low rate of porphyrin
Figure 1
Description of the kindred. Subjects I-1 and II-6–II-13 were examined.
Patients II-6, II-7, II-8, II-10, and II-12 had severe cutaneous lesions.
The mother (I-1) and three children (II-9, II-11, and II-13) were healthy.
The observation of the sibling II-11 is further discussed.
Table I. Porphyrin analyses in urine
Subject Clinical status ALA PBG Total porphyrins URO % COPRO %
II-6 CEP 1.88 0.52 29880 79 21
II-8 CEP 2.0 0.43 23440 68 32
II-12 CEP 1.43 0.32 43747 88 12
I-1 Healthy o50
II-9 Healthy o50
II-11 Healthy 2.82 o0.5 3049 79 21
Normal values No3
(mmol per mmol cr)
No0.5
(mmol per mmol cr)
No380
(nmol per liter)
Porphyrin accumulation from 24-h urine collection (cr¼creatinin) was determined by spectrophotometry. ALA, d-aminolevulinic acid; PBG, porp-
hobilinogen; URO, uroporphyrin; COPRO, coproporphyrin were extracted on chromatographic columns and quantitated by spectrophotometry. CEP,
congenital erythropoietic porphyria.
Table II. UROS enzymatic activity in erythrocytes
and genetic analysis
Subject Clinical status UROS activity Genotype
II-6 CEP o0.01 S47P/S47P
II-7 CEP nd S47P/S47P
II-8 CEP o0.01 S47P/S47P
II-12 CEP o0.01 S47P/S47P
I-1 Healthy 0.69 S47P/N
II-9 Healthy 1.05 S47P/N
II-11 Healthy o0.01 S47P/S47P
II-13 Healthy 2.56 N/N
Normal value (mean  1 SD) 3.1  0.7 nmol per h per mg
UROS enzymatic activity was determined by an enzyme-coupled assay
(Moreau-Gaudry et al, 1996). One unit was defined as the amount of
enzyme that formed 1 nmol of uroporphyrinogen III (URO III) per hour.
UROS-specific activity is expressed per mg of hemoglobin. CEP, con-
genital erythropoietic porphyria; UROS, uroporphyrinogen III synthase.
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accumulation associated with the profound enzymatic de-
ficiency in the sibling II-11.
This intriguing modifier may be a step on the way to
finding a new treatment of this severe disease. It would be a
valuable alternative to the only available curative treatment
for CEP, i.e. bone marrow transplantation (Verneuil et al,
2003).
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Figure 2
Identification of a newmutation of the uroporphyrinogen III synthase (UROS) gene. Informed consent was obtained from all adults and from the
parents of the children examined (eight members of the family). DNA was prepared from whole blood by the salting out procedure. The UROS gene
was amplified by PCR in ten fragments, nine corresponded to the exons 2–10, the last one covered the promoter region (Fontanellas et al, 1996;
Shady et al, 2002). Sequencing was performed using Big Dye Terminator sequencing kit on the ABI 377 automatic sequencer (Perkin-Elmer,
Courtaboeuf, France). The new mutation was detected in exon 3 of the UROS gene, the PCR fragment was sequenced in both directions. The
normal profile (sense strand) is -T TTC TCT GAG-, the homozygous mutant -T TTC CCT GAG-, the heterozygous mutant -T TTC T/C CT GAG-
encoding F–S–E, F–P–E, and F–S/P–E, respectively (residues 45–46–47). E, F, P, S is the single letter code for Glu, Phe, Pro, Ser.
Table III. Prokaryotic expression of the mutant S47P UROS
protein
Specific activity (SA: nmol per h per mg)
Mean SD Assays
Residual
activity (%)
pKK 0.41 0.08 2
pKK-UROS 180.26 8.2 2 100
pKK-S47P-UROS 5.74 1.24 3 2.8
The S47P mutant cDNA was obtained by site-directed mutagenesis in
the pKK 223.3 expression vector (Amersham-Pharmacia Saclay, France)
using the Gene Editor in vitro site-directed mutagenesis system (Promega,
Charbonnie`res, France). The integrity of the construct was checked by
sequencing. The analysis of bacterial lysates was performed as de-
scribed (Fontanellas et al, 1996).
SA is expressed per mg of total proteins in bacterial lysates.
Residual activity is the ratio: 100  (SA–SApKK)/(SApKK-UROS–SApKK).
UROS, uroporphyrinogen III synthase.
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